Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma stocks buck the trend
Mon, 9 Apr 11:30 am

Indian stock markets lost further ground after opening weak today. All sectoral indices are trading in the red except for pharmaceutical stocks.

The BSE-Sensex is trading down by 208 points and NSE-Nifty is trading lower by 70 points. BSE Mid Cap and BSE Small Cap indices are trading down by 0.9% and 0.3% respectively. The rupee is trading at 51.31 to the US dollar.

FMCG stocks are trading in the red led by Archies Limited and Henkel India. According to a leading financial daily, Marico will be raising Rs 5 bn through issue of shares. These shares will be issued to foreign investors namely Indivest and Baring India Private Equity Fund III. The company's board has approved to allot 29,411,764 shares of Re 1 each at an issue price of Rs 170 per share. Indivest would be allotted 22,058,823 shares amounting to Rs 3.75 bn. The issue size for Baring India will be Rs 1.25 bn. We may note here that Indivest is an affiliate of Government of Singapore Investment Corporation Pte Ltd and Baring is a Mauritius based firm. Marico has also decided to alter its authorized share capital. The company will cancel 50 m unissued preference shares of Rs 10 each and create 500 m equity shares of Rs 1 each.

Indian pharma stocks are trading strong led by Dishman Pharma and Ranbaxy Lab. According to a leading financial daily, Cipla is looking at the European inhaler market with generic drug launches in those markets. Cipla has a product pipeline of 11 products. However, at present it is mainly looking at a share in the Seretide drug. By 2013, CIpla will be launching Seretide in the European Union market. The other players in race for launching this drug in Europe include Teva, Mylan and Sandoz. Cipla has a market share of 70% in the inhalation therapy segment in India. Worldwide this market is estimated at US$ 34 bn and US and Europe are the major markets for this segment.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma stocks buck the trend". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.